Payment overview · 2025
General Payments
$87.61
5 reported records · 2 companies
Healthcare provider profile · identity verified
Arun Puthusseril, MD
Allopathic & Osteopathic Physicians|Family Medicine · SCRANTON, PA · NPI 1710453972
Verified facts
What the public records show
CMS Open Payments records show Arun Puthusseril, MD received $87.61 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 68.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Wegovy.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.56 | 68.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.05 | 32.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $87.61 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.56 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.05 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 129 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
129 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 77 |
| Lisinopril | Lisinopril | 387 | 87 |
| Alprazolam | Alprazolam | 322 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 221 | 41 |
| Bupropion Xl | Bupropion Hcl | 215 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 41 |
| Prednisone | Prednisone | 163 | 111 |
| Azelastine Hcl | Azelastine Hcl | 154 | 68 |
| Gabapentin | Gabapentin | 151 | 38 |
| Mounjaro | Tirzepatide | 147 | 28 |
| Lorazepam | Lorazepam | 143 | 27 |
| Omeprazole | Omeprazole | 135 | 41 |
| Tramadol Hcl | Tramadol Hcl | 135 | 42 |
| Furosemide | Furosemide | 132 | 33 |
| Glipizide Er | Glipizide | 131 | 43 |
| Farxiga | Dapagliflozin Propanediol | 130 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 30 |
| Trulicity | Dulaglutide | 113 | 28 |
| Ozempic | Semaglutide | 109 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 31 |
| Warfarin Sodium | Warfarin Sodium | 104 | suppressed |
| Jardiance | Empagliflozin | 103 | 24 |
| Trazodone Hcl | Trazodone Hcl | 102 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 20 |
| Clonazepam | Clonazepam | 92 | 17 |
| Potassium Chloride | Potassium Chloride | 92 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 32 |
| Eliquis | Apixaban | 81 | 15 |
| Montelukast Sodium | Montelukast Sodium | 77 | 15 |
| Losartan Potassium | Losartan Potassium | 75 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 19 |
| Pregabalin | Pregabalin | 69 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 23 |
| Amoxicillin | Amoxicillin | 52 | 40 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 12 |
| Sertraline Hcl | Sertraline Hcl | 51 | suppressed |
| Metformin Hcl | Metformin Hcl | 50 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 49 | 43 |
| Loperamide | Loperamide Hcl | 48 | 13 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Glipizide Xl | Glipizide | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 16 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 31 |
| Simvastatin | Simvastatin | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 26 |
| Diclofenac Potassium | Diclofenac Potassium | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 16 |
| Finasteride | Finasteride | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 21 |
| Ibuprofen | Ibuprofen | 24 | 14 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Wegovy | Semaglutide | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Erythromycin | Erythromycin Base | 13 | 11 |
| Tradjenta | Linagliptin | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $87.61 · 5 records | Novo Nordisk Inc | TRELEGY ELLIPTA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error